AC
HAE icon

Allstate Corporation’s Haemonetics HAE Stock Holding History

Allstate Corporation’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$586K Buy
7,807
+146
+2% +$9.38K 0.01% 966
2026
Q1 		$432K Buy
+7,661
New +$499K ﹤0.01% 1029
2022
Q1 		– Sell
-9,609
Closed -$510K – 663
2021
Q4 		$510K Sell
9,609
-193
-2% -$11.8K 0.01% 674
2021
Q3 		$692K Buy
9,802
+1,331
+16% +$84K 0.03% 409
2021
Q2 		$565K Buy
8,471
+3,267
+63% +$231K 0.02% 489
2021
Q1 		$578K Hold
5,204
– – 0.02% 499
2020
Q4 		$618K Buy
5,204
+165
+3% +$17.8K 0.02% 411
2020
Q3 		$440K Buy
5,039
+1,422
+39% +$124K 0.01% 454
2020
Q2 		$324K Sell
3,617
-39
-1% -$3.94K 0.01% 557
2020
Q1 		$364K Buy
3,656
+1,914
+110% +$208K 0.01% 435
2019
Q4 		$200K Buy
+1,742
New +$211K ﹤0.01% 608

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Corporation's HAE Position: Q2 2026 in Review

Allstate Corporation increased its Haemonetics (HAE) stake by 1.9% in Q2 2026, buying an estimated $9.38K and bringing the position to 7,807 shares worth $586K. The position accounts for 0.01% of the portfolio, ranked #966.

Allstate Corporation first reported a position in HAE in Q4 2019 and has held it in 11 quarters since. The position peaked at $692K in Q3 2021. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Allstate Corporation held 7,807 shares of Haemonetics worth $586K as of Q2 2026.
  • Allstate Corporation bought 146 Haemonetics shares in Q2 2026, an estimated $9.38K.
  • Haemonetics made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #966 holding.
  • Allstate Corporation first reported a position in Haemonetics in Q4 2019 and has held it in 11 quarters since.
  • Allstate Corporation's Haemonetics position peaked at $692K in Q3 2021.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.